Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% Higher – Time to Buy?

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC)’s stock price traded up 11.6% during trading on Thursday . The stock traded as high as $8.30 and last traded at $8.3340. 969,787 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 1,861,488 shares. The stock had previously closed at $7.47.

Key Oric Pharmaceuticals News

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: ORIC selected rinzimetostat 400 mg QD as the recommended Phase 3 (RP3D) dose in combination with darolutamide for the Himalayas‑1 registrational trial, moving the program toward a global Phase 3 start (initiation expected 1H 2026). GlobeNewswire Release
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $25 price target, signaling continued analyst conviction and a sizeable upside thesis from current levels. TickerReport
• Neutral Sentiment: Wedbush trimmed its price target from $20 to $17 but kept an “outperform” rating — still positive relative to the market price but a pullback in near‑term target. Benzinga
• Neutral Sentiment: Unusually large options flow: ~2,266 call contracts traded (a >2,000% rise vs. average), which can amplify intraday moves and reflects speculative/leveraged bullish interest. (No single-direction guarantee — could reflect hedging or directional bets.)
• Negative Sentiment: Market reaction driven by dose‑related safety/side‑effect signals in the Phase 1b rinzimetostat + darolutamide data; outlets reported steep intraday drops after the update. Investors appear focused on tolerability at higher doses despite moving to Phase 3. Yahoo Finance
• Negative Sentiment: Additional coverage and sell‑side commentary highlighted the safety concerns and valuation risk, contributing to follow‑on selling and volatility. Investing.com

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ORIC shares. Citigroup increased their price target on shares of Oric Pharmaceuticals from $16.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Oric Pharmaceuticals in a research note on Thursday. Piper Sandler started coverage on Oric Pharmaceuticals in a report on Wednesday, January 7th. They set an “overweight” rating and a $22.00 price target for the company. Wedbush reduced their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Oric Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $19.90.

Oric Pharmaceuticals Stock Up 10.7%

The stock has a market cap of $829.96 million, a price-to-earnings ratio of -5.44 and a beta of 1.36. The company has a 50 day simple moving average of $11.62 and a 200 day simple moving average of $11.31.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.04. As a group, analysts predict that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Insider Transactions at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total value of $702,520.00. Following the completion of the transaction, the chief financial officer owned 68,148 shares in the company, valued at $920,679.48. This trade represents a 43.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.82% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Oric Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Corient Private Wealth LLC bought a new stake in shares of Oric Pharmaceuticals in the 4th quarter valued at about $102,000. Invesco Ltd. increased its holdings in shares of Oric Pharmaceuticals by 19.8% during the fourth quarter. Invesco Ltd. now owns 109,742 shares of the company’s stock valued at $898,000 after acquiring an additional 18,128 shares in the last quarter. XTX Topco Ltd acquired a new position in Oric Pharmaceuticals during the fourth quarter worth $904,000. VARCOV Co. bought a new position in Oric Pharmaceuticals in the 4th quarter valued at about $262,000. Finally, Virtus Investment Advisers LLC lifted its holdings in shares of Oric Pharmaceuticals by 141.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 28,361 shares of the company’s stock valued at $232,000 after purchasing an additional 16,594 shares in the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.